RU2415847C9 - Новые производные циклопента[b]бензофурана и их применение - Google Patents
Новые производные циклопента[b]бензофурана и их применение Download PDFInfo
- Publication number
- RU2415847C9 RU2415847C9 RU2006144710/04A RU2006144710A RU2415847C9 RU 2415847 C9 RU2415847 C9 RU 2415847C9 RU 2006144710/04 A RU2006144710/04 A RU 2006144710/04A RU 2006144710 A RU2006144710 A RU 2006144710A RU 2415847 C9 RU2415847 C9 RU 2415847C9
- Authority
- RU
- Russia
- Prior art keywords
- carbon atoms
- formula
- ethoxy
- hydrogen
- alkyl
- Prior art date
Links
- 0 *c1cc(*)c(C(CO2)=O)c2c1 Chemical compound *c1cc(*)c(C(CO2)=O)c2c1 0.000 description 6
- GHPODDMCSOYWNE-UHFFFAOYSA-N Cc(cc1)cc2c1OCO2 Chemical compound Cc(cc1)cc2c1OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 3
- XSOAXIGWVKZJLJ-YRFIBDEKSA-N C/N=C(\C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCl)c2)c2ccccc2)/[C@]13O Chemical compound C/N=C(\C[C@H]([C@]1(c(cc2)ccc2Cl)Oc2c3ccc(OCCCl)c2)c2ccccc2)/[C@]13O XSOAXIGWVKZJLJ-YRFIBDEKSA-N 0.000 description 1
- ALIIAYWLXQCOJB-UHFFFAOYSA-N CC(Nc1ccc(C(CO2)=O)c2c1)=O Chemical compound CC(Nc1ccc(C(CO2)=O)c2c1)=O ALIIAYWLXQCOJB-UHFFFAOYSA-N 0.000 description 1
- UPNQXSSPZOFQJQ-NBSGVIAVSA-N CCC1=C(C)C(C)[IH]C(C[C@H](CN)[C@@H](CC2)[IH]CC2=C)=C1 Chemical compound CCC1=C(C)C(C)[IH]C(C[C@H](CN)[C@@H](CC2)[IH]CC2=C)=C1 UPNQXSSPZOFQJQ-NBSGVIAVSA-N 0.000 description 1
- SECDMPRMOZLRRU-OSPRVTPDSA-N CCOc1cc(O[C@@]([C@@H](C[C@H]2O)c(cccc3)c3[N](C)(C)C=O)([C@@]22O)c(cc3)ccc3Cl)c2cc1 Chemical compound CCOc1cc(O[C@@]([C@@H](C[C@H]2O)c(cccc3)c3[N](C)(C)C=O)([C@@]22O)c(cc3)ccc3Cl)c2cc1 SECDMPRMOZLRRU-OSPRVTPDSA-N 0.000 description 1
- PFNDRVNSZXZHSG-RNJDCESWSA-N CN(C)CCOc1cc(O[C@@]([C@@H](CC2)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 Chemical compound CN(C)CCOc1cc(O[C@@]([C@@H](CC2)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 PFNDRVNSZXZHSG-RNJDCESWSA-N 0.000 description 1
- DFKBSGITZGYABG-UHFFFAOYSA-N COCCOc1c(C(CO2)=O)c2ccc1 Chemical compound COCCOc1c(C(CO2)=O)c2ccc1 DFKBSGITZGYABG-UHFFFAOYSA-N 0.000 description 1
- UVZXLQXYMUHINJ-UQTORGHUSA-N COCCOc1cccc(O[C@]2(C(CC=O)c3ccccc3)c(cc3)ccc3Cl)c1C2=O Chemical compound COCCOc1cccc(O[C@]2(C(CC=O)c3ccccc3)c(cc3)ccc3Cl)c1C2=O UVZXLQXYMUHINJ-UQTORGHUSA-N 0.000 description 1
- QJFKKFMXDGNORM-BYXVTNLJSA-N COCCOc1cccc(O[C@]2([C@@H](CC3)c4ccccc4)c(cc4)ccc4Cl)c1[C@@]23O Chemical compound COCCOc1cccc(O[C@]2([C@@H](CC3)c4ccccc4)c(cc4)ccc4Cl)c1[C@@]23O QJFKKFMXDGNORM-BYXVTNLJSA-N 0.000 description 1
- PSTZFHLCQDAOJQ-UCEFQSHXSA-N Nc1cc(O[C@@]([C@@H](CC2O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 Chemical compound Nc1cc(O[C@@]([C@@H](CC2O)c3ccccc3)([C@@]22O)c(cc3)ccc3Cl)c2cc1 PSTZFHLCQDAOJQ-UCEFQSHXSA-N 0.000 description 1
- BUZFKXULXBOQRH-UHFFFAOYSA-N O=C(COc1c2)c1ccc2OCCCl Chemical compound O=C(COc1c2)c1ccc2OCCCl BUZFKXULXBOQRH-UHFFFAOYSA-N 0.000 description 1
- YCFNZVIQDUCPPD-UHFFFAOYSA-N O=C(Nc1ccc(C(CO2)=O)c2c1)OCc1ccccc1 Chemical compound O=C(Nc1ccc(C(CO2)=O)c2c1)OCc1ccccc1 YCFNZVIQDUCPPD-UHFFFAOYSA-N 0.000 description 1
- KGOHWTXRISFRLH-DOUMQJFESA-N O[C@]1(CC[C@H]2c3ccccc3)c(c(OCCN3CCCC3)ccc3)c3O[C@]12c(cc1)ccc1Cl Chemical compound O[C@]1(CC[C@H]2c3ccccc3)c(c(OCCN3CCCC3)ccc3)c3O[C@]12c(cc1)ccc1Cl KGOHWTXRISFRLH-DOUMQJFESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004024504.5 | 2004-05-18 | ||
| DE102004024504A DE102004024504A1 (de) | 2004-05-18 | 2004-05-18 | Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2006144710A RU2006144710A (ru) | 2008-06-27 |
| RU2415847C2 RU2415847C2 (ru) | 2011-04-10 |
| RU2415847C9 true RU2415847C9 (ru) | 2011-08-10 |
Family
ID=35207782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006144710/04A RU2415847C9 (ru) | 2004-05-18 | 2005-05-14 | Новые производные циклопента[b]бензофурана и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8030347B2 (https=) |
| EP (1) | EP1751127B1 (https=) |
| JP (1) | JP2007538031A (https=) |
| KR (1) | KR101215164B1 (https=) |
| CN (1) | CN1989122B (https=) |
| AU (1) | AU2005245104B2 (https=) |
| BR (1) | BRPI0510403A (https=) |
| CA (1) | CA2567404C (https=) |
| DE (1) | DE102004024504A1 (https=) |
| IL (1) | IL179257A (https=) |
| MX (1) | MXPA06013182A (https=) |
| RU (1) | RU2415847C9 (https=) |
| WO (1) | WO2005113529A2 (https=) |
| ZA (1) | ZA200609444B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1693059A1 (en) * | 2005-02-22 | 2006-08-23 | Deutsches Krebsforschungszentrum | Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases |
| EP2189453A1 (en) * | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Rocaglaol derivatives as cardioprotectant agents |
| EP2457907A1 (en) * | 2010-11-16 | 2012-05-30 | Université de Strasbourg | Flavagline derivatives as neuroprotective agents |
| US20140255432A1 (en) * | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| FR3023290B1 (fr) * | 2014-07-04 | 2016-08-19 | Pf Medicament | Derives de flavaglines |
| EP3888658B1 (en) | 2015-11-25 | 2023-12-27 | Effector Therapeutics, Inc. | Eif4-a-inhibiting compounds and methods related thereto |
| EP3755693B1 (en) | 2018-02-19 | 2024-06-12 | Memorial Sloan-Kettering Cancer Center | Agents and methods for treating dysproliferative diseases |
| EP3639820A1 (en) | 2018-10-16 | 2020-04-22 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Flavagline derivatives for inhibition of kras oncogene activation |
| CN110646616B (zh) * | 2019-09-05 | 2023-05-30 | 桂林理工大学 | 一种检测血清中人cTnI的超敏荧光猝灭免疫传感器及检测方法 |
| CN110776486B (zh) * | 2019-10-23 | 2022-05-20 | 中国药科大学 | 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用 |
| CA3230542A1 (en) | 2021-09-01 | 2023-03-09 | Krishnaraj Rajalingam | Novel ras inhibitors |
| CN116077483A (zh) * | 2021-11-05 | 2023-05-09 | 上海中医药大学 | 楝酰胺及其类似物的药物用途 |
| CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
| WO2024175662A1 (en) | 2023-02-23 | 2024-08-29 | KHR Biotec GmbH | Flavagline derivatives as ras inhibitors |
| JP2026508161A (ja) | 2023-02-23 | 2026-03-10 | エスジェーピー バイオテック ゲーエムベーハー | 新規ＲＡＳ阻害剤３ａＨ－シクロペンタ［ｂ］ベンゾフラン－３ａ－イル |
| WO2025092976A1 (zh) * | 2023-11-03 | 2025-05-08 | 映恩生物制药（苏州）有限公司 | 蛋白翻译抑制剂 |
| TW202545938A (zh) * | 2024-01-16 | 2025-12-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 一種蛋白轉譯抑制劑的偶聯物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1424735A3 (ru) * | 1984-01-13 | 1988-09-15 | Хиноин Дьедьсер Еш Ведьесети Термекек Дьра Рт (Инопредприятие) | Способ получени производных 7-оксопростациклина |
| RU2138498C1 (ru) * | 1994-07-22 | 1999-09-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе |
| WO2000007579A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN |
| WO2000008007A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | Cyclopentabenzofuran-derivate und ihre verwendung |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19934952A1 (de) * | 1998-07-30 | 2000-02-03 | Novartis Ag | Cyclopentabenzofuran-Derivate |
| DE10158561A1 (de) * | 2001-11-29 | 2003-06-12 | Bayer Ag | Neue Verwendung von Cyclopentabenzofuranen |
-
2004
- 2004-05-18 DE DE102004024504A patent/DE102004024504A1/de not_active Withdrawn
-
2005
- 2005-05-14 US US11/596,907 patent/US8030347B2/en not_active Expired - Fee Related
- 2005-05-14 EP EP05747405A patent/EP1751127B1/de not_active Expired - Lifetime
- 2005-05-14 BR BRPI0510403-3A patent/BRPI0510403A/pt not_active IP Right Cessation
- 2005-05-14 JP JP2007517059A patent/JP2007538031A/ja active Pending
- 2005-05-14 CN CN2005800241153A patent/CN1989122B/zh not_active Expired - Fee Related
- 2005-05-14 CA CA2567404A patent/CA2567404C/en not_active Expired - Fee Related
- 2005-05-14 MX MXPA06013182A patent/MXPA06013182A/es active IP Right Grant
- 2005-05-14 RU RU2006144710/04A patent/RU2415847C9/ru not_active IP Right Cessation
- 2005-05-14 AU AU2005245104A patent/AU2005245104B2/en not_active Ceased
- 2005-05-14 WO PCT/EP2005/005298 patent/WO2005113529A2/de not_active Ceased
-
2006
- 2006-11-14 IL IL179257A patent/IL179257A/en not_active IP Right Cessation
- 2006-11-14 ZA ZA200609444A patent/ZA200609444B/en unknown
- 2006-11-17 KR KR1020067024170A patent/KR101215164B1/ko not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1424735A3 (ru) * | 1984-01-13 | 1988-09-15 | Хиноин Дьедьсер Еш Ведьесети Термекек Дьра Рт (Инопредприятие) | Способ получени производных 7-оксопростациклина |
| RU2138498C1 (ru) * | 1994-07-22 | 1999-09-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе |
| WO2000007579A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | VERWENDUNG VON CYCLOPENTABENZOFURANDERIVATEN ZUR BEKÄMPFUNG VON NF-λB-ABHÄNGIGEN KRANKHEITEN |
| WO2000008007A2 (de) * | 1998-08-05 | 2000-02-17 | Bayer Aktiengesellschaft | Cyclopentabenzofuran-derivate und ihre verwendung |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005245104A1 (en) | 2005-12-01 |
| DE102004024504A1 (de) | 2006-02-16 |
| CN1989122B (zh) | 2013-07-24 |
| ZA200609444B (en) | 2008-01-30 |
| RU2006144710A (ru) | 2008-06-27 |
| JP2007538031A (ja) | 2007-12-27 |
| IL179257A0 (en) | 2007-03-08 |
| RU2415847C2 (ru) | 2011-04-10 |
| EP1751127B1 (de) | 2012-07-11 |
| US20090018113A1 (en) | 2009-01-15 |
| EP1751127A2 (de) | 2007-02-14 |
| WO2005113529A2 (de) | 2005-12-01 |
| KR20070011522A (ko) | 2007-01-24 |
| WO2005113529A3 (de) | 2006-02-09 |
| US8030347B2 (en) | 2011-10-04 |
| KR101215164B1 (ko) | 2012-12-24 |
| CA2567404C (en) | 2014-04-01 |
| IL179257A (en) | 2013-02-28 |
| AU2005245104B2 (en) | 2011-07-28 |
| CA2567404A1 (en) | 2005-12-01 |
| BRPI0510403A (pt) | 2007-10-23 |
| MXPA06013182A (es) | 2007-02-14 |
| CN1989122A (zh) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2415847C9 (ru) | Новые производные циклопента[b]бензофурана и их применение | |
| EP3917616B1 (en) | Heterocyclic compounds and use thereof | |
| CN111051295B (zh) | 杂环化合物及其用途 | |
| JP7408569B2 (ja) | 複素環化合物 | |
| JP7413261B2 (ja) | 複素環化合物およびその用途 | |
| JP7749263B2 (ja) | Ｋａｔ６阻害剤としての化合物 | |
| EP2961745B1 (en) | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors | |
| WO2018164192A1 (ja) | 置換ピロリジン化合物およびその用途 | |
| CN115003670A (zh) | 杂环化合物 | |
| WO2018024188A1 (zh) | 多环化合物、其制备方法、药物组合物及应用 | |
| JP2016510033A (ja) | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 | |
| WO2015060368A1 (ja) | 複素環化合物 | |
| HK1203943A1 (en) | Quinazolinedione derivative | |
| CN120641412A (zh) | 杂环化合物及其用途 | |
| CN112752760B (zh) | 杂环化合物 | |
| WO2001083452A1 (en) | Novel tricyclic compounds | |
| JP2023524935A (ja) | 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物 | |
| FR2953836A1 (fr) | Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75 | |
| HK1108885A (en) | Novel cylopenta[b]benzofuran derivatives and the utilization thereof | |
| JPWO2002024641A1 (ja) | セロトニン受容体親和性を有する三環性インドール化合物 | |
| CN121057736A (zh) | 大环杂环化合物及其用途 | |
| HK40051268A (en) | A heterocyclic compound, preparation method therefor, and use | |
| HK40057687B (en) | Heterocyclic compounds and use thereof | |
| HK40057687A (en) | Heterocyclic compounds and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Reissue of patent specification | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140515 |